Ascentage Pharma Group International (AAPG)
$17.25 -0.14 (-0.81%)| Market Cap | N/A |
| Revenue (ttm) | N/A |
| Net Income (ttm) | N/A |
| EPS (ttm) | N/A |
| PE Ratio | N/A |
| Forward PE | N/A |
| Profit Margin | N/A |
| Debt to Equity Ratio | N/A |
| Volume | 315,441 |
| Avg Vol | N/A |
| Day's Range | N/A - N/A |
| Shares Out | N/A |
| Stochastic %K | N/A |
| Beta | N/A |
| Analysts | N/A |
| Price Target | N/A |
Latest News on AAPG
Mar 27, 2025, 3:04 PM EDT - 11 days ago
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
Mar 25, 2025, 7:00 PM EDT - 12 days ago
Ascentage Pharma to Present Five Preclinical Studies from Innovative Pipeline at American Association of Cancer Research (AACR) Annual Meeting 2025
Mar 12, 2025, 8:46 AM EDT - 26 days ago
Ascentage Pharma to Report Full Year 2024 Financial Results and Provide Corporate Update on March 27, 2025
Mar 5, 2025, 6:00 PM EST - 4 weeks ago
Olverembatinib Granted Breakthrough Therapy Designation for the Treatment of Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
Feb 7, 2025, 8:24 AM EST - 2 months ago
Ascentage Pharma Announces Partial Exercise of Underwriters' Option to Purchase Additional American Depositary Shares
Jan 28, 2025, 4:01 PM EST - 2 months ago
Ascentage Pharma Announces Closing of U.S. Initial Public Offering
Jan 23, 2025, 6:41 PM EST - 2 months ago
Ascentage Pharma Announces Pricing of U.S. Initial Public Offering
Dec 27, 2024, 4:53 PM EST - 3 months ago
Ascentage Pharma Group International IPO Registration Document (F-1)